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On the Cover
Left: Physician Mina Pastagia, a Clinical
Scholar who is studying a novel treatment
for staphylococcal skin infections in
psoriasis patients.
Center: Virologist Charles Rice, a leader in
the study of hepatitis C, with postdoctoral
investigator Catherine Murray.
Right: Melissa Offenhartz (at left), director
of nursing and patient care services, and
nursing assistant Olga Ford.

A .REVOLUTIONARY IDEA
For more than a century, The Rockefeller University has stood at the
forefront of biomedical discovery. Founded in 1901 as the nation's first
medical research center, Rockefeller has long been a world leader in the
effort to understand human health and
disease. Rockefeller's research hospital,
which opened its doors in 1910, was the
country's first clinical research hospital
and the birthplace of clinical research in the
United States. A hospital unlike any other at
the time, this facility was devoted to clinical
investigation and to translating laboratory
discoveries into new approaches to diag
nosing, treating, and preventing disease.
The revolutionary idea on which the
Hospital was founded is as alive today
as it was in 1910. The rise of molecular
biology, born in the Rockefeller Hospital
in 1944, has opened previously unimagined
therapeutic possibilities. Thus, translating
basic discoveries into medical treatments
and preventions is more important than
ever. More and more, both basic scientists and physician-scientists are
exploring medical applications of their discoveries. The Hospital's expert
and dedicated staff and I are doing all we can to support the efforts of
these gifted investigators and to train the next generation of clinical
research leaders.
Barry S. Coller, M.D.
Physician-in-Chief
The Rockefeller University Hospital

EXTRAORDINARY BREAKTHROUGHS
The Rockefeller Hospital has been the site of myriad breakthroughs that
have advanced the treatment and prevention of disease, including the
discovery that DNA is the carrier of genetic information-the finding
that launched the modern biological revolution. Rockefeller researchers
were also the first to:
• demonstrate that a virus can cause cancer
• confirm the connection between cholesterol and heart disease
• create effective vaccines for meningitis and pneumonia
• develop animal models for the study of heart disease and
multiple sclerosis
• discover blood types and ways to preserve whole blood, making
blood banks possible
• pioneer clinical studies based on the dendritic cell, a key immune
system cell discovered at Rockefeller
• demonstrate that the body's metabolism adjusts to maintain a set
weight, helping to explain why weight loss is so difficult
• develop drug combinations that offered the first life-extending
treatments for HIV and AIDS
• discover an obesity gene and a weight-regulating hormone, leptin
• devise methadone treatment to manage heroin addiction
• develop a rationally designed antiplatelet therapy, which improved
the results of coronary artery stenting
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Above: The Rockefeller University Hospital,
which has been extensively renovated
over the past decade, houses a 20-bed
inpatient unit and an outpatient center, as
well as state-of-the-art laboratories for
principal investigators.
Right: World-renowned AIDS investigator
David Ho administers a new vaccine under
study to a volunteer at the Hospital.
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LEADING THE WAY IN CLINICAL RESEARCH
AND MOLECULAR MEDICINE
Biomedical scientists associated with the Hospital conduct research that is
innovative and influential. They are creating new "smart" drugs, designing
and testing therapeutic and preventative vaccines, and introducing a host
of other medical interventions that emanate from the latest laboratory
findings. Working at the cutting edge of molecular medicine and clinical
investigation, the University's researchers are developing:
• Precise molecular markers that can be used to plan cancer treatment,
based on a Rockefeller scientist's discovery of several microRNAs
that disable tumor metastasis. MicroRNAs, tiny molecular entities
that were unknown 20 years ago, are now recognized as determi
nants of health and disease.
• New methods using microRNAs to identify disease-relevant genetic
variations in individuals with fragile X syndrome, which is strongly
associated with _autism. These technologies will eventually contribute
to custom-designed treatments for a range of disorders.
• A "nanosyringe" for intracellular delivery of protein therapeutics,
re-engineered from a mechanism that some bacteria use to inject
toxins into host cells.
• New ways to prevent and treat rare childhood infections as well as
global diseases such as tuberculosis, based on a Rockefeller scien
tist's revolutionary work that is revealing inborn immune deficien
cies that confer vulnerability to specific microorganisms.
• New ways to fight MRSA and other antibiotic-resistant bacteria with
an enzyme isolated from a phage-a virus that kills bacteria. This
could dramatically reduce the incidence of resistant infections
acquired in hospitals, a leading cause of death in the elderly.
• New therapeutic regimens for melanoma based on knowledge
acquired from state-of-the-art molecular genetic and imaging studies.
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• Recommendations regarding the effectiveness of vitamin D in
preventing cardiovascular disease.
• A broad-spectrum therapy to suppress autoimmunity, the harmful
attack by the immune system against the body's own cells that can
result in rheumatoid arthritis, type 1 diabetes, and lupus.

Right: The Hospital's nursing staff plays an
essential role in clinical investigations.
Below: Physician-scientist Agata
Smogorzewska with a member of her
laboratory. A Rockefeller alumna, she
returned to the University in 2009 as an
assistant professor.
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CLINICAL SCHOLARS
The Clinical Scholars Program at The Rockefeller University Hospital
addresses one of the most pressing needs in biomedicine: the training of
physician-scientists who are qualified to conduct research in both the
laboratory and the clinic. The three-year program is designed to provide
an optimal environment and mentoring structure in which young physi
cians gain the experience and capabilities necessary to initiate indepen
dent careers as patient-oriented and translational investigators.
Most applicants to the program are physicians who have recently com
pleted their residency or subspecialty fellowship. Each Clinical Scholar
becomes affiliated with at least
one Rockefeller research group
and carries out patient-oriented
translational research under
the mentorship of the head of
laboratory. This independent
research is complemented by a
rigorous core curriculum in
clinical and translational inves
tigation. The program leads to
a master's degree in clinical and
translational research.
Current and recent Clinical
Scholars conduct or have con
ducted innovative biological
research on a broad spectrum
of medical problems, including tumor immunity and
tumor immunotherapy, the regulation of dietary cholesterol absorption,
platelet physiology and thrombosis, the autoimmune basis of psoriasis,
the role of the hormone leptin in obesity, HIV infection and treatment,
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the development of vaccines for HIV, immune dysregula<tion associated
with hepatitis C, the molecular and genetic bases of addiction, and a
range of questions in basic immunology.
Although most Clinical Scholars are associated with Hospital-based
laboratories, several Scholars have joined basic research groups to initi
ate and carry out projects that integrate recent findings in biology with
patient-based studies. Topics addressed by these Clinical Scholars include liver inflammation, the
cause of chronic lymphocytic
Left: Clinical Scholar Dana Orange with Robert Darnell, head
leukemia and lymphomas, and
of the Laboratory of Molecular Neuro-oncology.
the application of RNA biology
to kidney disease and neurodeBelow: Immunologist Marina Caskey (at right) with colleagues.
generative disorders.
A former Clinical Scholar, Dr. Caskey continues to conduct HIV
vaccine research at Rockefeller under a career development
award from the National Institutes of Health.

DISTINGUISHED FACULTY
Faculty currently affiliated with the Rockefeller Hospital include such
outstanding investigators as:
Jan L. Breslow, M.D., former president of the American Heart

Association, who has pioneered the use of DNA technology to study
heart disease.
Senior Attending Physician, Frederick Henry Leonhardt Professor
Laboratory of Biochemical Genetics and Metabolism

Jean-Laurent Casanova, M.D., Ph.D., who received the 2008 Richard

Lounsbery Award for discoveries about genetic vulnerabilities to viral
and bacterial diseases of childhood.
Senior Attending Physician, Professor
St. Giles Laboratory of Human Genetics of Infectious Diseases

Barry S. Coller, M.D., a leader in vascular biology, who developed an
F.D.A. approved antiplatelet therapy and created a test to monitor the
effectiveness of aspirin and clopidogrel (Plavix) in individual patients.
Physician-in-Chief, Vice President for Medical Affairs
David Rockefeller Professor
Allen and Frances Adler Laboratory of Blood and Vascular Biology

Robert B. Darnell, M.D., Ph.D., whose work is shedding light on
autoimmunity, neurodegenerative diseases, and cancer.
Senior Attending Physician, Robert and Harriet Heilbrunn Professor
Laboratory of Molecular Neuro-oncology
Investigator, Howard Hughes Medical Institute

Vincent A. Fischetti, Ph.D., who is developing novel antibacterial

strategies against MRSA, strep, anthrax, and other pathogens.
Professor
Laboratory of Bacterial Pathogenesis and Immunology

8

Top: National Medal of Science recipient Elaine Fuchs with

Above: Physician-scientists Jean-Laurent Casanova (at

President Barack Obama.

left) and Sohail Tavazoie, who recently established new
laboratories at the University.

Above: Microbiologist Vincent Fischetti.
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Albert Lasker Award recipients Jeffrey Friedman, below, and
Ralph Steinman, right. Dr. Friedman discovered the appetite
regulating hormone leptin. Dr. Steinman identified dendritic cells,
key components of the body's immune system.
Mary Jeanne Kreek, bottom at center, has been an international
leader in establishing addiction studies as a vital branch of
biomedical science.

Jeffrey M. Friedman, M.D., Ph.D., who received a 201Q Albert Lasker
Award for his discovery of the obesity gene and the weight-regulating
hormone leptin.
Marilyn M. Simpson Professor
Laboratory of Molecular Genetics
Director, Starr Center for Human Genetics
Investigator, Howard Hughes Medical Institute

Elaine Fuchs, Ph.D., recipient of a National Medal of Science in 2009
for her innovative research on skin stem cells.
Rebecca C. Lancefield Professor
Laboratory of Mammalian Cell Biology and Development
Investigator, Howard Hughes Medical Institute

David D. Ho, M.D., who is at the forefront of efforts to develop
HIV vaccines and other prevention strategies.
Senior Physician, Irene Diamond Professor
Scientific Director and Chief Executive Officer, Aaron Diamond AIDS Research Center

Mary Jeanne Kreek� M.D., a pioneer researcher in addiction
biology who helped develop methadone maintenance therapy for
heroin addiction.
Senior Attending Physician, Patrick E. and Beatrice M. Haggerty Professor
Laboratory of the Biology of Addictive Diseases

James G. Krueger, M.D., Ph.D., noted for his discoveries about
psoriasis, who also heads a major initiative on melanoma.
Senior Attending Physician, D. Martin Carter Professor
Laboratory for Investigative Dermatology
Director, Milstein Medical Research Program

Michel C. Nussenzweig, M.D., Ph.D., who is designing immuno
therapies for HIV, cancer, diabetes, and other disorders.
Senior Physician, Sherman Fairchild Professor
Laboratory of Molecular Immunology
Investigator, Howard Hughes Medical Institute
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Jeffrey V. Ravetch, M.D., Ph.D., who studies immune mechanisms and
is developing new therapies for autoimmune disorders.
Theresa and Eugene M. Lang Professor
Leonard Wagner Laboratory of Molecular Genetics and Immunology

Charles M. Rice, Ph.D., who is a leading authority on the hepatitis C
virus, one of the main causes of liver cancer.
Maurice R. and Corinne P. Greenberg Professor
Laboratory of Virology and Infectious Disease
Director, Center for the Study of Hepatitis C

Agata Smogorzewska, M.D., Ph.D., who uses a hereditary genome
instability syndrome, Fanconi anemia, as a model for understanding
the cellular aging process and cancer.
Assistant Professor
Laboratory of Genome Maintenance

Ralph M. Steinman, M.D., who received the 2007 Albert Lasker
Award for his discovery of the dendritic cell, which is now a focus of
study in laboratories ·worldwide.
Senior Physician, Henry G. Kunkel Professor
Laboratory of Cellular Physiology and Immunology
Director, Christopher H. Browne Center for Immunology and Immune Diseases

Sohail Tavazoie, M.D., Ph.D., who studies small molecules that block
tumor metastasis in an effort to improve cancer diagnosis and treatment.
Senior Attending Physician, Leon Hess Assistant Professor
Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology

Leslie B. Vosshall, Ph.D., whose studies of human olfaction are leading
to a deeper understanding of neurosensory disorders.
Robin Chemers Neustein Professor
Laboratory of Neurogenetics and Behavior
Investigator, Howard Hughes Medical Institute
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FROM THE BOARD CHAIR
I first became involved with The Rockefeller University because of
the . Hospital. Some years ago my daughter was seen by Rockefeller
doctors. She suffered from psoriasis-not a life-threatening condition
but decidedly a quality-of-life-threatening one. At the time, I knew little
about the University. I observed that she received excellent
Above: Board Chair
care. In return, my family had the satisfaction of knowing
Russell Carson with
that her participation was contributing to research that
Professor Leslie Vosshall.
might one day provide a cure.
My curiosity aroused, I began attending events at the University to
find out more about it. What I learned so impressed me that I eagerly
accepted an invitation to join the Board in 1994. In the years since, as
my knowledge has deepened, so has my appreciation-indeed, my awe
of the University and its remarkable team of scientists and physicians.
Their contributions to medical science have been profound.
Russell L. Carson
Chair, The Rockefeller University
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OVERVIEW OF THE ROCKEFELLER UNIVERSITY
Scientifically and geographically, The Rockefeller University Hospital
stands at the heart of a world-renowned center for biomedical investi
gation and graduate education. The Rockefeller University is dedicated
to research that will improve the understanding of life for the benefit
of humanity.
Founded in 1901 as The Rockefeller Institute for Medical Research, the
University was the nation's first institution devoted exclusively to bio
medical science. It was renamed The Rockefeller University in 1965.

A Community of Scholars
Today, the University comprises more than 70 independent laborato
ries. The Rockefeller community includes 300 research and clinical
scientists, 350 postdoctoral investigators, 200 graduate students,
and 1,050 technical and administrative personnel, all working at the
University's 14-acre campus.

A Unique Open Structure
Since its founding, The Rockefeller University has embraced an open
structure to encourage collaborations between disciplines and empower
faculty members to take on high-risk, high-reward projects. No formal
departments exist, bureaucracy is kept to a minimum, and scientists
are given resources, support, and unparalleled freedom to follow their
research wherever it leads.

Areas of Investigation
Rockefeller's scientists conduct research in six broad areas: biochemistry
and structural biology; molecular, cell, and developmental biology;
medical sciences and human genetics; immunology, microbiology, and
virology; neuroscience; and physics and mathematical biology. In
addition, eight interdisciplinary centers focus on Alzheimer's disease,
cancer, hepatitis C, and other biomedical concerns.
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Award-Winning Science
Rockefeller University's unique approach has led to some of the world's
most revolutionary contributions in biology and medicine. Over the
years, 23 Nobel laureates have been associated with Rockefeller, includ
ing two alumni. In addition, the University has been home to 21 recipi
ents of the Albert Lasker Medical Research Award, 14 National Medal
of Science recipients, and 14 Gairdner Foundation International award
ees. Thirty-five members of the current faculty have been elected to the
National Academy of Sciences.

An Exceptional Place to Learn
More than 1,000 scientists have received Rockefeller Ph.D. degrees
since the graduate program began in 1955. Providing opportunities to
conduct the highest quality science, the program attracts exceptional
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students from around the world. The Rockefeller University also
sponsors one of the nation's top M.D.-Ph.D. programs with neighbor
ing Memorial Sloan-Kettering Cancer Center and Weill Cornell
Medical College. In addition, at any
one time, several hundred postdoctoral
investigators receive advanced training
and conduct research in Rockefeller's
laboratories.

Funding for New Science
At Rockefeller, the research enterprise
and educational programs are support
ed by government and private grants
and contracts, private philanthropy,
and income from the endowment. The
University's annual operating budget
totals more than $310 million.

Key Partnerships
Rockefeller has close ties to Memorial
Sloan-Kettering Cancer Center, Weill
Cornell Medical College, New York
Presby terian Hospital, and other lead
ing institutions. In addition, 14 Univer
sity scientists are Howard Hughes
Medical Institute Investigators-the
highest percentage of HHMI Investi
gators on any biomedical faculty in the
country. Rockefeller also forges col
laborations with biotech and pharma
ceutical companies to speed research
findings into development and improve
patient care.
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Rockefeller University Trustee Judith Roth Berkowitz,
a member of the Board's Hospital Committee, with
Physician-in-Chief Barry Coller.
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Ms. Kate Kadoun
Senior Director, Outreach Initiatives
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